BerGenBio AS has raised NOK 75 million ($12.5 million) with a private equity placement to finance development of its lead drug candidate, BGB324, which is in Phase 1b studies. The compound is said to interfere with cancer drug resistance and metastases.
Anergis SA of Switzerland has raised CHF 8 million (€6.5 million) from its venture capital backers in order to advance its lead vaccine product, AllerT, for birch pollen allergy into Phase 3 development.
Smith & Nephew Plc of the UK is acquiring ArthroCare Corp of the US in a move that will strengthen its position in sports medicine. The value of the deal is $1.7 billion, or about $1.5 billion when ArthroCare’s cash reserves are taken into account.
Crossject SA, a French company with a needle-free pharmaceutical injection system designed for self-administration, is issuing 1,538,462 shares in an initial public offering on the NYSE Alternext exchange in Paris.
Ablynx NV has secured a new research collaboration with Merck & Co based on its technology for antibody-derived therapeutic proteins – this time to discover and develop candidate drugs th
Germany-based Medigene AG, which has a long history in oncology drug discovery, has acquired Trianta Immunotherapies GmbH of Munich, a spin-out with three T cell immunotherapy technologies. The value of the deal is €4 million plus milestones.
Genmab A/S has raised DKK 998 million (€134 million) following the pricing of a previously-announced private share placement to support development of its therapeutic antibody portfolio. The company announced the results on 24 January.
IP Group Plc, which invests in intellectual property generated by universities primarily in the UK, has decided to raise new capital with a share issue. Funds from the issue will enable the company to expand its portfolio of life science investments.
Seventure Partners, an indirect subsidiary of the French financial conglomerate, Natixis SA, has launched a new fund called Health for Life Capital that will invest in companies focused on nutrition and the science relating to the human microbiome.
JLL/Delta Dutch Newco BV, a company set up to combine the assets of Canada’s Patheon Inc and the pharmaceutical division of Royal DSM of the Netherlands, is raising $500 million with a private placement of eight-year notes in New York.